Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik Rasmussen

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Blood|April 24, 2004
RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myelomaChristopher A Maxwell, Erik Rasmussen, Fenghuang Zhan, et al.
American Journal of Hematology|April 4, 2017
A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemiaHagop M Kantarjian, Michael W Schuster, Nitin Jain, et al.
Investigational New Drugs|July 8, 2018
A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumorsMichael Carducci, Montaser Shaheen, Ben Markman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2010
Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumorsAlain C Mita, Chris H Takimoto, Monica Mita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2009
Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumorsRoy S Herbst, David Hong, Linnea Chap, et al.
Current Medical Research and Opinion|May 10, 2021
Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancerGebra Cuyun Carter, Kristin M Sheffield, Anala Gossai, et al.
The New England Journal of Medicine|March 10, 2006
Thalidomide and hematopoietic-cell transplantation for multiple myelomaBart Barlogie, Guido Tricot, Elias Anaissie, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|July 14, 2010
Primary endothelial damage is the mechanism of cardiotoxicity of tubulin-binding drugsIgor Mikaelian, Andreas Buness, Maria-Cristina de Vera-Mudry, et al.
Clinical Genitourinary Cancer|December 25, 2013
A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinomaDavid S Hong, Michael S Gordon, Wolfram E Samlowski, et al.
Investigational New Drugs|July 31, 2019
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myelomaW Larry Gluck, Mrinal M Gounder, Richard Frank, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Blood|April 24, 2004
RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myelomaChristopher A Maxwell, Erik Rasmussen, Fenghuang Zhan, et al.
American Journal of Hematology|April 4, 2017
A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemiaHagop M Kantarjian, Michael W Schuster, Nitin Jain, et al.
Investigational New Drugs|July 8, 2018
A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumorsMichael Carducci, Montaser Shaheen, Ben Markman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2010
Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumorsAlain C Mita, Chris H Takimoto, Monica Mita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2009
Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumorsRoy S Herbst, David Hong, Linnea Chap, et al.
Current Medical Research and Opinion|May 10, 2021
Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancerGebra Cuyun Carter, Kristin M Sheffield, Anala Gossai, et al.
The New England Journal of Medicine|March 10, 2006
Thalidomide and hematopoietic-cell transplantation for multiple myelomaBart Barlogie, Guido Tricot, Elias Anaissie, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|July 14, 2010
Primary endothelial damage is the mechanism of cardiotoxicity of tubulin-binding drugsIgor Mikaelian, Andreas Buness, Maria-Cristina de Vera-Mudry, et al.
Clinical Genitourinary Cancer|December 25, 2013
A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinomaDavid S Hong, Michael S Gordon, Wolfram E Samlowski, et al.
Investigational New Drugs|July 31, 2019
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myelomaW Larry Gluck, Mrinal M Gounder, Richard Frank, et al.
Pageof 5